Hong Kong Study Using Valsartan in IgA Nephropathy (HKVIN): A Double-Blind, Randomized, Placebo-Controlled Study

American Journal of Kidney Diseases

Volumn 47, Issue 5, 2006, Pages 751-760

  Li, Philip Kam Tao ^a,b,c,d,e,f   Leung, Chi Bon ^a,b,c,d,e,f   Chow, Kai Ming ^a,b,c,d,e,f   Cheng, Yuk Lun ^a,b,c,d,e,f   Fung, Samuel Ka Shun ^a,b,c,d,e,f   Mak, Siu Ka ^a,b,c,d,e,f   Tang, Anthony Wing Chung ^a,b,c,d,e,f   Wong, Teresa Yuk Hwa ^a,b,c,d,e,f   Yung, Chun Yu ^a,b,c,d,e,f   Yung, Jonathan Chee Unn ^a,b,c,d,e,f   Yu, Alex Wai Yin ^a,b,c,d,e,f   Szeto, Cheuk Chun ^a,b,c,d,e,f  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b ALICE HO MIU LING NETHERSOLE HOSPITAL   (Hong Kong)

^c PRINCESS MARGARET HOSPITAL   (Hong Kong)

^d KWONG WAH HOSPITAL   (Hong Kong)

^e TUEN MUN HOSPITAL   (Hong Kong)

^f UNITED CHRISTIAN HOSPITAL   (Hong Kong)

Author keywords

angiotensin receptor blocker; Glomerulonephritis; proteinuria; renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; PLACEBO; VALSARTAN;

ADULT; ALLERGY; ANGIONEUROTIC EDEMA; ANKLE EDEMA; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIALYSIS; DIZZINESS; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HEART FAILURE; HEART PALPITATION; HONG KONG; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY FAILURE; MALE; OUTCOME ASSESSMENT; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; GLOMERULONEPHRITIS, IGA; HONG KONG; HUMANS; MALE; TETRAZOLES; VALINE;

EID: 33646483060     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.01.017     Document Type: Article

References (31)

1. Li P.K., Ho K.K., Szeto C.C., Yu L., and Lai F.M. Prognostic indicators of IgA nephropathy in the Chinese-Clinical and pathological perspectives. Nephrol Dial Transplant 17 (2002) 64-69
2. 51Cr-EDTA clearance. Kidney Int 40 (1991) 1050-1054
3. D'Amico G. The commonest glomerulonephritis in the world. IgA nephropathy. Q J Med 245 (1987) 709-727
4. Alexopoulos E. Treatment of primary IgA nephropathy. Kidney Int 65 (2004) 341-355
5. Donadio J.V., and Grande J.P. IgA nephropathy. N Engl J Med 347 (2002) 738-748
6. 1 receptor blocker, on the glomerular fibrosis of IgA nephropathy in ddY mice. Nephron 86 (2000) 374-375
7. Park H.C., Xu Z.G., Choi S., et al. Effect of losartan and amlodipine on proteinuria and transforming growth factor-β1 in patients with IgA nephropathy. Nephrol Dial Transplant 18 (2003) 1115-1121
8. Song J.H., Lee S.W., Suh J.H., et al. The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy. Clin Nephrol 60 (2003) 318-326
9. Nakao N., Yoshimura A., Morita H., Takada M., Kayano T., and Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE). A randomized controlled trial. Lancet 361 (2003) 117-124
10. Levy A.S., Coresh J., Balk E., et al. National Kidney Foundation Practice Guidelines for Chronic Kidney Disease. Evaluation, classification, and stratification. Ann Intern Med 139 (2003) 137-147
11. Locatelli F., Del Vecchio L., and Andrulli S. REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet 352 (1998) 2020-2021
12. Ruggenenti P., Perna A., Gherardi G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354 (1999) 359-364
13. Hedeker D., and Gibbons R.D. MIXREG. A computer program for mixed-effects regression analysis with autocorrelated errors. Comput Methods Prog Biomed 49 (1996) 229-252
14. Taal M.W., and Brenner B.M. Renoprotective benefits of RAS inhibition. from ACEI to angiotensin II antagonists. Kidney Int 57 (2000) 1803-1817
15. Levey A.S., Greene T., Beck G.J., et al. Dietary protein restriction and the progression of chronic renal disease. What have all of the results of the MDRD Study shown? Modification of Diet in Renal Disease Study group. J Am Soc Nephrol 10 (1999) 2426-2439
16. Bartosik L.P., Lajoie G., Sugar L., and Cattran D.C. Predicting progression in IgA nephropathy. Am J Kidney Dis 38 (2001) 728-735
17. Donadio J.V., Bergstralh E.J., Offord K.P., Spencer D.C., and Holley K.E. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 331 (1994) 1194-1199
18. van Ypersele de Strihou C. Fish oil for IgA nephropathy?. N Engl J Med 331 (1994) 1227-1229
19. Campbell R., Sangalli F., Perticucci E., et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 63 (2003) 1094-1103
20. Reddan D.N., and Owen Jr. W.F. IgA nephropathy and inhibitors of the renin angiotensin system. Is reduction in proteinuria adequate proof of efficacy. Am J Kidney Dis 38 (2001) 182-185
21. Ballardie F.W. IgA nephropathy treatment 25 years on: Can we halt progression? The evidence base. Nephrol Dial Transplant 19 (2004) 1041-1046
22. Maschio G., Cagnoli L., Claroni F., et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy. A multicenter, randomized, placebo-controlled study. Nephrol Dial Transplant 9 (1994) 265-269
23. Bannister K.M., Weaver A., Clarkson A.R., and Woodroffe A.J. Effect of angiotensin-converting enzyme and calcium channel inhibition on progression of IgA nephropathy. Contrib Nephrol 111 (1995) 184-192
24. Cheng I., Fang G., Wong M., Ji Y., Chan K., and Yeung H. A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy. Nephrology 4 (1998) 19-26
25. Cattran D.C., Greenwood C., and Ritchie S. Long-term benefit of angiotensin-converting enzyme inhibitor therapy in patients with severe immunoglobulin A nephropathy. A comparison to patients receiving treatment with other antihypertensive agents and to patients receiving no therapy. Am J Kidney Dis 23 (1994) 247-254
26. Russo D., Minutolo R., Pisani A., et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38 (2003) 18-25
27. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43 suppl 1 (2004) S1-S290
28. Ruggenenti P., Perna A., Gherardi G., Gaspari F., Benini R., and Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 352 (1998) 1252-1256
29. Wright Jr. J.T., Bakris G., Greene T., and African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease. Results from the AASK Trial. JAMA 288 (2002) 2421-2431
30. Contreras G., Greene T., Agodoa L.Y., and African American Study of Kidney Disease and Hypertension Study Group Investigators. Blood pressure control, drug therapy, and kidney disease. Hypertension 46 (2005) 44-50
31. Leung W.Y., So W.Y., Tong P.C., et al. The renoprotective effects of structured care in a clinical trial setting in type 2 diabetic patients with nephropathy. Nephrol Dial Transplant 19 (2004) 2519-2525